NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, today announced that the company will
participate in the RBC Capital Markets 2018 Global Healthcare Conference
in New York, NY.
President and Chief Executive Officer, Dan Browne, is scheduled to
participate in a fireside chat discussion on Wednesday, February 21 at
Interested parties can access the live audio webcast for this conference
from the Investor Relations section of the company’s website at www.revance.com.
The webcast replay will be available after the conclusion of the live
presentation for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company developing
neuromodulators for use in treating aesthetic and underserved
therapeutic conditions, including muscle movement disorders and pain.
The company’s lead drug candidate, DaxibotulinumtoxinA for Injection
(RT002), is currently in development for the treatment of glabellar
lines, cervical dystonia and plantar fasciitis, with the potential to be
the first long-acting neuromodulator. Revance has developed a
proprietary, stabilizing excipient peptide technology designed to create
novel, differentiated therapies. The company has a comprehensive
pipeline based upon its peptide technology, including injectable and
topical formulations of daxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
Revance Therapeutics, Inc.: